Millenium Biologix Inc. Enters Into Asset Sale Agreement for Skelite(TM) Technology

KINGSTON, ONTARIO -- (MARKET WIRE) -- April 30, 2007 -- Millenium Biologix Corporation ("Millenium" or the "Company") (TSX: MBC) today announced that it and its wholly-owned subsidiary Millenium Biologix Technologies Inc. ("MBTI") entered into an agreement with Medtronic of Canada Ltd. and Warsaw Orthopedic, Inc. (collectively, the "Purchasers") for the sale of MBTI's resorbable synthetic bone graft technology, Skelite™ to the Purchasers. Under the terms of the agreement, Millenium will receive a closing payment and may also subsequently receive certain milestone and contingent payments.